o-chloro-DL-tyrosine | 54788-41-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: o-chloro-DL-tyrosine
• 英文别名: 2-Amino-3-(2-chloro-4-hydroxyphenyl)propanoic acid
• CAS: 54788-41-9
• 化学式: C₉H₁₀ClNO₃
• 分子量: 215.636
• InChiKey: QGFVUADZXXJSDI-UHFFFAOYSA-N

物化性质

• 沸点：
  408.9±45.0 °C(Predicted)
• 密度：
  1.458±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氯-4-甲氧基溴苄 在 氢溴酸 作用下， 生成 o-chloro-DL-tyrosine
  参考文献：
  名称：

  Synthesis and microbiological activities of some monohalogenated analogs of tyrosine

  摘要：

  2-Chlorotyrosine and 2-bromotyrosine, as well as the previously reported 2-fluorotyrosine, were synthesized by hydrolysis of the condensation products from the appropriate benzyl bromide and ethyl acetamidomalonate and were compared with the corresponding 3-halotyrosines as growth inhibitors of Escherichia coli 9723, Streptococcus faecalis 8043 and Lactobacillus plantarum 8014. In contrast to the 2- and 3-fluorotyrosines which were equally effective as growth inhibitors, the 2-chloro- and 2-bromotyrosines were much more effective than the 3-chloro- and 3-bromotyrosines in inhibiting the growth of the three microorganisms. For each of the assay organisms, the growth inhibitions of all three 2-halotyrosines were reversed competitively in varying degrees by tyrosine.

  DOI：

  10.1021/jm00235a006

文献信息

• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS
  申请人：Hoffman Technologies, Inc.

  公开号：EP3655036A1

  公开（公告）日：2020-05-27
• Receptor-binding cyclic peptides and methods of use
  申请人：Sutcliffe-Goulden Julie

  公开号：US20060029544A1

  公开（公告）日：2006-02-09

  The present invention provides novel receptor-binding cyclic peptides that advantageously display high receptor binding affinity and selectively. More particularly, the present invention provides integrin-binding cyclic peptides containing an integrin-binding motif such as an RGD motif, an aromatic amino acid such as a tyrosine residue, and a lysine residue having a pi-pi stacking moiety conjugated to its ε-amino group. Methods for identifying receptor-binding cyclic peptides and for using the cyclic peptides of the present invention for imaging a tumor, organ, or tissue and for treating cancer, inflammatory diseases, and autoimmune diseases are also provided.
• [EN] RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE<br/>[FR] PEPTIDES CYCLIQUES DE LIAISON A UN RECEPTEUR ET LEURS METHODES D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2006017619A2

  公开（公告）日：2006-02-16

  The present invention provides novel receptor-binding cyclic peptides that advantageously display high receptor binding affinity and selectively. More particularly, the present invention provides integrin-binding cyclic peptides containing an integrin-binding motif such as an RGD motif, an aromatic amino acid such as a tyrosine residue, and a lysine residue having a pi-pi stacking moiety conjugated to its -amino group. Methods for identifying receptor-binding cyclic peptides and for using the cyclic peptides of the present invention for imaging a tumor, organ, or tissue and for treating cancer, inflammatory diseases, and autoimmune diseases are also provided.
• [EN] COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES LIÈS AU STRESS
  申请人：HOFFMAN TECH INC

  公开号：WO2019018633A1

  公开（公告）日：2019-01-24

  The present inventions relate generally to compositions, kits, and methods for the treatment of stress-related disorders, including but not limited to post-traumatic stress disorder.